Trever G. Bivona, Ph.D.

2004 New York University, New York, NY, United States 
Cell Biology, Molecular Biology
"Trever Bivona"
Mean distance: (not calculated yet)


Sign in to add mentor
Mark R. Philips grad student 2004 NYU
 (Compartmentalized signaling by Ras family GTPases.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Chou YT, Bivona TG. (2022) Inhibition of SHP2 as an approach to block RAS-driven cancers. Advances in Cancer Research. 153: 205-236
Tulpule A, Guan J, Neel DS, et al. (2021) Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell
Kerr DL, Haderk F, Bivona TG. (2021) Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology. 62: 1-12
Maynard A, McCoach CE, Rotow JK, et al. (2020) Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell
Negrao MV, Raymond VM, Lanman RB, et al. (2020) Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer
Lotsberg ML, Wnuk-Lipinska K, Terry S, et al. (2020) AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug resistant cancer cells. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer
Wu W, Okimoto RA, Blakely CM, et al. (2020) Targeted DNA sequencing analysis to reveal genetic diversity and androgen-receptor alteration in advanced EGFR mutant lung adenocarcinoma. Journal of Clinical Oncology. 38: 9526-9526
Haderk F, Allegakoen D, Guan J, et al. (2020) Abstract PR11: Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC Molecular Cancer Research. 18
Zaman A, Bivona T. (2020) Abstract B36: Therapy-induced YAP hyperactivation is a mechanism driving the evolution of residual disease and resistance to targeted cancer therapy Molecular Cancer Research. 18
Haderk F, Fernández-Méndez C, Shah K, et al. (2020) B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC Journal of Thoracic Oncology. 15: S27
See more...